🇺🇸 FDA
Patent

US 8323706

Antiestrogenic glyceollins suppress human breast and ovarian carcinoma proliferation and tumorigenesis

granted A61KA61K36/48A61P

Quick answer

US patent 8323706 (Antiestrogenic glyceollins suppress human breast and ovarian carcinoma proliferation and tumorigenesis) held by The United States of America, as represented by the Secretary of Agriculture expires Mon Nov 29 2032 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Secretary of Agriculture
Grant date
Tue Dec 04 2012 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Nov 29 2032 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
1
CPC classes
A61K, A61K36/48, A61P, A61P35/00